JP2018527895A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527895A5
JP2018527895A5 JP2017568233A JP2017568233A JP2018527895A5 JP 2018527895 A5 JP2018527895 A5 JP 2018527895A5 JP 2017568233 A JP2017568233 A JP 2017568233A JP 2017568233 A JP2017568233 A JP 2017568233A JP 2018527895 A5 JP2018527895 A5 JP 2018527895A5
Authority
JP
Japan
Prior art keywords
seq
hybridoma cell
cell line
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017568233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527895A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/040011 external-priority patent/WO2017004151A1/en
Publication of JP2018527895A publication Critical patent/JP2018527895A/ja
Publication of JP2018527895A5 publication Critical patent/JP2018527895A5/ja
Pending legal-status Critical Current

Links

JP2017568233A 2015-06-29 2016-06-29 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法 Pending JP2018527895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186109P 2015-06-29 2015-06-29
US62/186,109 2015-06-29
PCT/US2016/040011 WO2017004151A1 (en) 2015-06-29 2016-06-29 Anti-apobec3 antibodies and methods of making and using

Publications (2)

Publication Number Publication Date
JP2018527895A JP2018527895A (ja) 2018-09-27
JP2018527895A5 true JP2018527895A5 (https=) 2019-08-22

Family

ID=57609413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017568233A Pending JP2018527895A (ja) 2015-06-29 2016-06-29 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法

Country Status (4)

Country Link
US (1) US10752699B2 (https=)
EP (1) EP3313993A4 (https=)
JP (1) JP2018527895A (https=)
WO (1) WO2017004151A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313993A4 (en) 2015-06-29 2019-06-19 Regents of the University of Minnesota ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
WO2020190609A1 (en) * 2019-03-15 2020-09-24 Mayo Foundation For Medical Education And Research Oncolytic viruses and methods for using oncolytic viruses
CN114341178B (zh) * 2019-07-02 2024-05-07 机敏医药股份有限公司 Ccl14的抗体和检测
WO2021087462A1 (en) * 2019-10-31 2021-05-06 The Research Foundation For The State University Of New York Rage antibodies, fragments and uses thereof
CA3231704A1 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
CN117802095B (zh) * 2024-03-01 2024-06-25 广东工业大学 一种检测核酸胞嘧啶脱氨酶apobec3b活性的化学发光试剂盒及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888458A4 (en) 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
US20110111424A1 (en) * 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
ATE506456T1 (de) 2003-06-10 2011-05-15 David Gladstone Inst Verfahren zur behandlung von lentivirusinfektionen
US8133666B2 (en) 2004-11-02 2012-03-13 The J. David Gladstone Institutes Method for identifying agents capable of inhibiting APOBEC3C activity in HIV-infected cells
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
RU2008152193A (ru) 2006-06-15 2010-07-20 Бёрингер Ингельхайм Интернациональ Гмбх (De) 2-амино-4-аминоалкиленаминопиримидины
US8999317B2 (en) * 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
EP2036988A1 (en) 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2010006214A1 (en) * 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
US9084762B2 (en) * 2008-09-30 2015-07-21 The Regents Of The University Of California T-cell immunogens derived from anti-viral proteins and methods of using same
US20120252026A1 (en) 2011-04-01 2012-10-04 Harris Reuben S Cancer biomarker, diagnostic methods, and assay reagents
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP2812016A2 (en) 2012-02-12 2014-12-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cellular apobec3 proteins and modulators thereof for regulating dna repair processes and treating proliferative disease
AU2013302861A1 (en) 2012-08-13 2015-03-05 The Rockefeller University Treatment and diagnosis of melanoma
HU230680B1 (hu) 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
MX2015016978A (es) * 2013-06-10 2016-04-25 Merck Sharp & Dohme Proteinas de union a antigeno neutralizantes de citomegalovirus.
EP3041859A2 (en) 2013-09-03 2016-07-13 INSERM - Institut National de la Santé et de la Recherche Médicale Compositions and methods for inducing senescence in cancer cells
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
GB201420859D0 (en) 2014-11-24 2015-01-07 Cancer Res Inst Royal Tumour analysis
EP3314025A4 (en) 2015-06-29 2019-04-24 Regents of the University of Minnesota APOBEC3B MUTAGENESIS AND IMMUNOTHERAPY
EP3313993A4 (en) 2015-06-29 2019-06-19 Regents of the University of Minnesota ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE
US20180185302A1 (en) 2015-06-30 2018-07-05 Regents Of The University Of Minnesota Methods for downregulating apobec3b
US20190085405A1 (en) 2016-03-23 2019-03-21 Regents Of The University Of Minnesota Methods of detecting apobec3 expression and predicting clinical outcomes

Similar Documents

Publication Publication Date Title
JP2018527895A5 (https=)
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2017518366A5 (https=)
JP2018042573A5 (https=)
JP2017524725A5 (https=)
JP2016026303A5 (https=)
HRP20250850T1 (hr) Antitijela protiv claudina 18.2 korisna u dijagnozi raka
JP2013506428A5 (https=)
HRP20160461T1 (hr) Solubilna humana st-2 antitijela i eseji
Akter et al. Broad-spectrum noncompetitive immunocomplex immunoassay for cyanobacterial peptide hepatotoxins (microcystins and nodularins)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2016505634A5 (https=)
JP2016516400A5 (https=)
JP2021520492A5 (https=)
JP2010539161A5 (https=)
JP2010526880A5 (https=)
JP2016512242A (ja) Ｈｃｖコア脂質結合ドメインモノクローナル抗体
JP2020516603A5 (https=)
JP2016500659A5 (https=)
RU2013142334A (ru) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а
JP7557023B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2020189843A5 (https=)
CN107921123A (zh) 骆驼源单域hcv抗体以及使用方法
JP7455947B2 (ja) アデノウイルスの免疫測定方法及び免疫測定器具
JP2017538786A5 (https=)